This is a routine equity-compensation-related sale by an officer with negligible market impact. No actionable trading signal — monitor for any subsequent Form 4 filings to confirm the sale was executed, but the filing itself is not a material event.
Price Chart
Executive Summary
Douglas Earl Martin, an officer of Allogene Therapeutics, filed a Form 144 notice of intent to sell 29,697 shares of common stock, with an approximate market value of $62,958. The shares were acquired via vesting of restricted stock units on August 20, 2026, under the issuer's equity compensation plan. This is a routine insider sale tied to equity compensation vesting, not a discretionary open-market sale, and the dollar amount is small relative to the company's $726M market cap, making the filing low-impact.
Key Facts
- Officer Douglas Earl Martin filed Form 144 to sell 29,697 shares of Allogene Therapeutics common stock.
- The shares were acquired via vesting of restricted stock units on August 20, 2026, under the issuer's equity compensation plan.
- The approximate market value of the proposed sale is $62,957.64.
- The sale is to be executed through Morgan Stanley Smith Barney LLC.
- The company's market cap is approximately $726M, making this sale less than 0.01% of market cap.
Financial Impact
Proposed sale of 29,697 shares valued at approximately $62,958, representing a small fraction of the officer's likely holdings and less than 0.01% of the company's $726M market cap.
Risk Factors
- Insider may still choose not to execute the sale despite filing the notice.
- No indication of broader insider selling pattern — this appears to be a single, small disposition tied to RSU vesting.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001737287-26-000023 |
| Document: 0001737287-26-000023-index.html | 0001737287-26-000023 |
| Document: 0001737287-26-000023.txt | 0001737287-26-000023 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $1.21 | awaiting T+1 | — | $1.23 (+1.65%) |
Oct 21, 2026 6d ago | 144 | $1.25 $1.25 | · 0.00% | ▲ +0.52% | $1.23 (−1.60%) |
Sep 2, 2026 7w ago | 8-K | $1.98 $1.98 | · 0.00% | ▼ −1.05% | $1.23 (−37.88%) |
Aug 21, 2026 9w ago | 144 | $2.03 $2.17 | ▲ +6.90% | ▲ +6.58% | $1.23 (−39.41%) |
Aug 21, 2026 9w ago | EFFECT | $2.09 $2.03 | ▲ +2.87% | ▲ +2.58% | $1.23 (+41.15%) |
Aug 6, 2026 11w ago | Institutional Cluster | $1.97 $2.01 | ▲ +2.03% | ▲ +1.42% | $1.23 (−37.56%) |
Jun 22, 2026 18w ago | 8-K | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.23 (+40.58%) |
Jun 22, 2026 18w ago | 424B5 | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.23 (+40.58%) |
May 28, 2026 21w ago | DEFA14A | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.23 (−43.32%) |
May 28, 2026 21w ago | 8-K | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.23 (−43.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers